


Stabilis



Hydromorphone hydrochloride



Noms commerciaux

Dilaudid	Canada, Etats Unis d'Amérique
Hydal	Autriche
Palladon	Danemark, Suisse
Palladone	Grande Bretagne











































































































Stabilité des solutions

		50 mg/ml	37°C		90			2305
PVC		1 & 5 mg/ml	23°C		42			120
PVC		1 & 5 mg/ml	4°C		42			120
PVC		0,2 & 10 mg/ml	23°C		90			4230
PVC		20 mg/ml	22°C		7			4664
PVC		20 mg/ml	37°C		7			4664
POF		0,2 & 10 mg/ml	23°C		90			4230
		0,1 mg/ml	25°C		100			4303
		0,1 mg/ml	30°C		30			5
		1,5 & 80 mg/ml	23°C		60			1706
		1,5 & 80 mg/ml	37°C		48			1706
		1,5 & 80 mg/ml	4°C		60			1706
		10 mg/ml	30°C		30			5
		0,2 mg/ml	20°C		112			2659
		0,2 mg/ml	35°C		112			2659
		0,2 mg/ml	5°C		112			2659
		10 mg/ml	37°C		120			1867



Stabilité en mélange

		0,25 mg/ml	20°C-23°C		Granisetron hydrochloride : 0,5 mg/ml	4		57
		0,2 mg/ml	25°C		Ketamine hydrochloride : 0,2 >> 1 mg/ml	7		2336
		0,05 mg/ml	25°C		Morphine hydrochloride : 0,25 mg/ml	15		4667
		0,05 mg/ml	37°C		Morphine hydrochloride : 0,25 mg/ml	15		4667
		0,1 & 1 mg/ml	23°C-25°C		Tacrolimus : 5 & 20 µg/ml	4		814
		2 & 10 & 40 mg/ml	23°C		Dimenhydrinate : 50 mg/ml	24		1497
		0,25 mg/ml	25°C		Palonosetron hydrochloride : 25 µg/ml	4		2196
		2 & 10 & 40 mg/ml	37°C		Dimenhydrinate : 50 mg/ml	24		1497
		2 & 10 & 40 mg/ml	4°C		Dimenhydrinate : 50 mg/ml	24		1497
		0,5 mg/ml	-20°C		Fluorouracil : 1 & 16 mg/ml	35		513
		0,5 mg/ml	23°C		Fluorouracil : 16 mg/ml	7		513
		0,5 mg/ml	23°C		Fluorouracil : 1 mg/ml	35		513
		0,5 mg/ml	32°C		Fluorouracil : 16 mg/ml	3		513
		0,5 mg/ml	32°C		Fluorouracil : 1 mg/ml	7		513
		0,5 mg/ml	4°C		Fluorouracil : 1 & 16 mg/ml	35		513
		20 mg/ml	22°C		Esketamine : 20 mg/ml	7		4664
		0,5 mg/ml	22°C		Ondansetron hydrochloride : 0,1 & 1 mg/ml	31		6
		0,02 & 0,1 mg/ml	23°C-25°C		Bupivacaine hydrochloride : 0,62 & 1,2 mg/ml	72		306
		0,2 mg/ml	25°C		Ketamine hydrochloride : 0,2 >> 1 mg/ml	7		2336
		0,05 mg/ml	25°C		Morphine hydrochloride : 0,25 mg/ml	15		4667
		0.0015 mg/ml	25°C		Bupivacaine hydrochloride : 0.5 mg/ml	30		4746
		0.03 mg/ml	25°C		Bupivacaine hydrochloride : 0.5 mg/ml	30		4746
		0.03 mg/ml	25°C		Bupivacaine hydrochloride : 2.5 mg/ml	30		4746
		0.0015 mg/ml	25°C		Bupivacaine hydrochloride : 2.5 mg/ml	30		4746
		0,5 mg/ml	32°C		Ondansetron hydrochloride : 0,1 & 1 mg/ml	7		6
		20 mg/ml	37°C		Esketamine : 20 mg/ml	7		4664
		0,05 mg/ml	37°C		Morphine hydrochloride : 0,25 mg/ml	15		4667
		0,5 mg/ml	4°C		Ondansetron hydrochloride : 0,1 & 1 mg/ml	31		6
		0.0015 mg/ml	4°C		Bupivacaine hydrochloride : 0.5 mg/ml	30		4746
		0.03 mg/ml	4°C		Bupivacaine hydrochloride : 0.5 mg/ml	30		4746

		0.03 mg/ml	4°C		Bupivacaine hydrochloride : 2.5 mg/ml	30		4746
		0.0015 mg/ml	4°C		Bupivacaine hydrochloride : 2.5 mg/ml	30		4746
		0,5 mg/ml	4°C-22°C		Ondansetron hydrochloride : 0,1 & 1 mg/ml	31		6
		0,5 mg/ml	4°C-22°C		Granisetron hydrochloride : 0,056 mg/ml	31		6
		0,5 mg/ml	4°C-22°C		Granisetron hydrochloride : 0,056 mg/ml	31		6
		0,05 mg/ml	25°C		Morphine hydrochloride : 0,25 mg/ml	15		4667
		0,05 mg/ml	37°C		Morphine hydrochloride : 0,25 mg/ml	15		4667
		0.0015 mg/ml	25°C		Bupivacaine hydrochloride : 0.5 mg/ml	30		4746
		0.03 mg/ml	25°C		Bupivacaine hydrochloride : 0.5 mg/ml	30		4746
		0.03 mg/ml	25°C		Bupivacaine hydrochloride : 2.5 mg/ml	30		4746
		0.0015 mg/ml	25°C		Bupivacaine hydrochloride : 2.5 mg/ml	30		4746
		0.0015 mg/ml	4°C		Bupivacaine hydrochloride : 0.5 mg/ml	30		4746
		0.03 mg/ml	4°C		Bupivacaine hydrochloride : 0.5 mg/ml	30		4746
		0.03 mg/ml	4°C		Bupivacaine hydrochloride : 2.5 mg/ml	30		4746
		0.0015 mg/ml	4°C		Bupivacaine hydrochloride : 2.5 mg/ml	30		4746
		0,02 & 0,04 mg/ml	22°C		Bupivacaine hydrochloride : 2,5 mg/ml	91		1931
		0,2 mg/ml	25°C		Ketamine hydrochloride : 0,2 >> 1 mg/ml	7		2336
		10 mg/ml	25°C		Scopolamine hydrobromide : 0,04 mg/ml Famotidine : 0,4 mg/ml Haloperidol lactate : 0,5 mg/ml Dimenhydrinate : 5 mg/ml	12		2166
		10 mg/ml	25°C		Famotidine : 0,4 mg/ml Midazolam hydrochloride : 1 mg/ml	96		2166
		10 mg/ml	25°C		Haloperidol lactate : 0,5 mg/ml Metoclopramide hydrochloride : 0,5 mg/ml	96		2166
		10 mg/ml	25°C		Famotidine : 0,4 mg/ml Metoclopramide hydrochloride : 0,5 mg/ml Ketoprofene : 1,5 mg	96		2166
		10 mg/ml	4°C		Scopolamine hydrobromide : 0,04 mg/ml Famotidine : 0,4 mg/ml Haloperidol lactate : 0,5 mg/ml Dimenhydrinate : 5 mg/ml	12		2166
		10 mg/ml	4°C		Famotidine : 0,4 mg/ml Midazolam hydrochloride : 1 mg/ml	96		2166
		10 mg/ml	4°C		Famotidine : 0,4 mg/ml Metoclopramide hydrochloride : 0,5 mg/ml Ketorolac tromethamine : 1,5 mg/ml	96		2166
		0,02 & 0,04 mg/ml	6°C		Bupivacaine hydrochloride : 2,5 mg/ml	91		1931
		0,08 mg/ml	24°C		Fentanyl citrate : 16 µg/ml Nefopam : 0,8 mg/ml Ramosetron : 12 µg/ml	4		4666

		0,08 mg/ml	24°C		Fentanyl citrate : 16 µg/ml Nefopam : 0,8 mg/ml Ondansetron hydrochloride : 0,32 mg/ml	4		4666
		2 & 20 mg/ml	23°C		Midazolam hydrochloride : 0.1 & 0.5 mg/ml	23		345
		2 & 20 mg/ml	4°C		Midazolam hydrochloride : 0.1 & 0.5 mg/ml	23		345
		35 mg/ml	37°C		Ziconotide acetate : 25 µg/ml	19		2251
		50 mg/ml	37°C		Bupivacaine hydrochloride : 24 mg/ml Clonidine hydrochloride : 2 mg/ml	90		2305
		15 mg/ml	37°C		Bupivacaine hydrochloride : 10 mg/ml	90		4200



Facteur influençant la stabilité

				1415
--	--	--	--	------



Compatibilités

	Hydromorphone hydrochloride : 0.04 mg/ml Aciclovir sodium : 5 mg/ml		336
	Hydromorphone hydrochloride : 0.5 mg/ml Allopurinol sodium : 3 mg/ml		307
	Hydromorphone hydrochloride : 0.5 mg/ml Amifostine : 10 mg/ml		3
	Hydromorphone hydrochloride : 0.2 mg/ml Amikacin sulfate : 5 mg/ml		405
	Hydromorphone hydrochloride : 10 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
			921
	Hydromorphone hydrochloride : 0.5 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
	Hydromorphone hydrochloride : 2 >> 40 mg/ml Ampicillin sodium : 20 & 250 mg/ml		226
	Hydromorphone hydrochloride : 0.2 mg/ml Ampicillin sodium : 20 mg/ml		405
	Hydromorphone hydrochloride : 0.5 mg/ml Amsacrine : 1 mg/ml		253
	Hydromorphone hydrochloride : 0.5 mg/ml Anidulafungin : 0.5 mg/ml		1982
	Hydromorphone hydrochloride : 0.5 mg/ml Atropine sulfate : 0.4 mg/ml		1974
	Hydromorphone hydrochloride : 0.5 mg/ml Aztreonam : 40 mg/ml		99
	Hydromorphone hydrochloride : 0.5 mg/ml Bivalirudin : 5 mg/ml		1713
	Hydromorphone hydrochloride : 0,02 & 0,04 mg/ml Bupivacaine hydrochloride : 2,5 mg/ml		1931

		Hydromorphone hydrochloride : 0,02 & 0,1 mg/ml Bupivacaine hydrochloride : 0,625 & 1,25 mg/ml		306
		Hydromorphone hydrochloride : 25 mg/ml Bupivacaine hydrochloride : 20 mg/ml		3131
		Hydromorphone hydrochloride : 1 mg/ml Caspofungin acetate : 0.5 mg/ml		2233
		Hydromorphone hydrochloride : 2 >> 40 mg/ml Cefazolin sodium : 20 mg/ml		226
		Hydromorphone hydrochloride : 2,5 mg/ml		4507
		Hydromorphone hydrochloride : 15 mg/ml Bupivacaine hydrochloride : 10 mg/ml		4200
		Hydromorphone hydrochloride : 65 mg/ml Bupivacaine hydrochloride : 7,5 mg/ml		221
		Hydromorphone hydrochloride : 50 mg/ml Caffeine : 10 mg/ml		3964
		Hydromorphone hydrochloride : 2 >> 40 mg/ml Cefazolin sodium : >200 mg/ml		226
		Hydromorphone hydrochloride : 1 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Hydromorphone hydrochloride : 0.2 mg/ml Cefmetazole sodium : 100 mg/ml		93
		Hydromorphone hydrochloride : 0,5 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Hydromorphone hydrochloride : 1 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Hydromorphone hydrochloride : 1 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Hydromorphone hydrochloride : 2 mg/ml Cimetidine hydrochloride : 150 mg/ml		1438
		Hydromorphone hydrochloride : 0.5 mg/ml Cladribine : 0.015 mg/ml		1496
		Hydromorphone hydrochloride : 2 >> 40 mg/ml Cloxacillin sodium : 40 & 250 mg/ml		226
		Hydromorphone hydrochloride : 0.5 mg/ml		301
		Hydromorphone hydrochloride : 0.5 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Hydromorphone hydrochloride : 0.5 mg/ml Cladribine : 0.5 mg/ml		1496
		Hydromorphone hydrochloride : 10 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Hydromorphone hydrochloride : 0.5 mg/ml		1415
		Hydromorphone hydrochloride : 1 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Hydromorphone hydrochloride : 0.2 mg/ml Cefalotin sodium : 20 mg/ml		405
		Hydromorphone hydrochloride : 0.2 mg/ml Cefamandole nafate : 20 mg/ml		405
		Hydromorphone hydrochloride : 0.2 mg/ml Cefazolin sodium : 20 mg/ml		405
		Hydromorphone hydrochloride : 0.2 mg/ml Cefoperazone sodium : 20 mg/ml		405

		Hydromorphone hydrochloride : 0.2 mg/ml Ceforanide : 20 mg/ml		405
		Hydromorphone hydrochloride : 0.2 mg/ml Cefotaxime sodium : 20 mg/ml		405
		Hydromorphone hydrochloride : 0.2 mg/ml Cefoxitin sodium : 20 mg/ml		405
		Hydromorphone hydrochloride : 0,5 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Hydromorphone hydrochloride : 2 >> 40 mg/ml Ceftazidime : 40 & 180 mg/ml		226
		Hydromorphone hydrochloride : 0.2 mg/ml Ceftizoxime sodium : 20 mg/ml		405
		Hydromorphone hydrochloride Ceftobiprole medocaril sodium		4650
		Hydromorphone hydrochloride : 1 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
		Hydromorphone hydrochloride : 0.2 mg/ml Cefuroxime sodium : 30 mg/ml		405
		Hydromorphone hydrochloride : 0.5 mg/ml Dexamethasone sodium phosphate : 1 mg/ml		1974
		Hydromorphone hydrochloride : 10 mg/ml	RL	4603
		Hydromorphone hydrochloride : 0.2 mg/ml Chloramphenicol sodium succinate : 20 mg/ml		405
		Hydromorphone hydrochloride : 0.2 mg/ml Clindamycin phosphate : 12 mg/ml		405
		Hydromorphone hydrochloride : 0.2 mg/ml Co-trimoxazole : 4/0.8 mg/ml		405
		Hydromorphone hydrochloride : > 15 mg/ml Dexamethasone sodium phosphate : > 3 mg/ml		389
		Hydromorphone hydrochloride : 1 >> 40 mg/ml Dexamethasone sodium phosphate : < 2 mg/ml		389
		Hydromorphone hydrochloride : < 10 mg/ml Dexamethasone sodium phosphate : 2 >> 10 mg/ml		389
		Hydromorphone hydrochloride : 0.5 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Hydromorphone hydrochloride : 2 >> 40 mg/ml Diazepam : 5 mg/ml		226
		Hydromorphone hydrochloride : 0.5 mg/ml Diazepam : 0.5 mg/ml		1974
		Hydromorphone hydrochloride : 1 mg/ml Diltiazem hydrochloride : 1 mg/ml		314
		Hydromorphone hydrochloride Dimenhydrinate		2087
		Hydromorphone hydrochloride : 2 >> 40 mg/ml Dimenhydrinate : 50 mg/ml		1497
		Hydromorphone hydrochloride : 0.5 mg/ml Diphenhydramine hydrochloride : 2 mg/ml		1974
		Hydromorphone hydrochloride : 1 mg/ml Dobutamine hydrochloride : 4 mg/ml		314
		Hydromorphone hydrochloride : 0.5 mg/ml Docetaxel : 0.9 mg/ml		1754

	Hydromorphone hydrochloride : 1 mg/ml Dopamine hydrochloride : 3.2 mg/ml		314
	Hydromorphone hydrochloride : 1 mg/ml Doripenem : 5 mg/ml		2262
	Hydromorphone hydrochloride : 0.5 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
	Hydromorphone hydrochloride : 0.2 mg/ml Doxycycline hyclate : 1 mg/ml		405
	Hydromorphone hydrochloride : 1 mg/ml Epinephrine hydrochloride : 20 µg/ml		314
	Hydromorphone hydrochloride : 1 mg/ml Eravacycline : 0,6 mg/ml		4434
	Hydromorphone hydrochloride : 0.2 mg/ml Erythromycin lactobionate : 5 mg/ml		405
	Hydromorphone hydrochloride : 0.5 mg/ml Etoposide phosphate : 5 mg/ml		1410
	Hydromorphone hydrochloride : 0.5 mg/ml Famotidine : 2 mg/ml		215
	Hydromorphone hydrochloride : 0.5 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
	Hydromorphone hydrochloride : 1 mg/ml Fentanyl citrate : 50 µg/ml		314
	Hydromorphone hydrochloride : 0.5 mg/ml Filgrastim : 30 µg/ml		244
	Hydromorphone hydrochloride : 0.5 mg/ml Fludarabine phosphate : 1 mg/ml		492
	Hydromorphone hydrochloride : 0.5 mg/ml Fluorouracil : 1 & 16 mg/ml		513
	Hydromorphone hydrochloride : 10 mg/ml Foscarnet sodium : 24 mg/ml		73
	Hydromorphone hydrochloride : 1 mg/ml Fosfomycin : 30 mg/ml		4055
	Hydromorphone hydrochloride : 1 mg/ml Furosemide : 10 mg/ml		314
	Hydromorphone hydrochloride : 4 mg/ml Gallium nitrate : 1 mg/ml		91
	Hydromorphone hydrochloride : 0.5 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
	Hydromorphone hydrochloride : 0.2 mg/ml Gentamicin sulfate : 0.8 mg/ml		405
	Hydromorphone hydrochloride : 0.5 mg/ml Granisetron hydrochloride : 1 mg/ml		57
	Hydromorphone hydrochloride : 0.5 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
	Hydromorphone hydrochloride : 0.5 mg/ml Granisetron hydrochloride : 0.056 mg/ml		6
	Hydromorphone hydrochloride : 10 mg/ml Haloperidol lactate : 1 mg/ml		216
	Hydromorphone hydrochloride : 10 mg/ml Haloperidol lactate : 2 mg/ml		216
	Hydromorphone hydrochloride : 10 mg/ml Haloperidol lactate : 5 mg/ml		216

		Hydromorphone hydrochloride : 1 mg/ml Haloperidol lactate : 5 mg/ml	∅	216
		Hydromorphone hydrochloride : 1 mg/ml Haloperidol lactate : 2 mg/ml	∅	216
		Hydromorphone hydrochloride : 1 mg/ml Haloperidol lactate : 1 mg/ml	∅	216
		Hydromorphone hydrochloride : 0.5 mg/ml Haloperidol lactate : 0.2 mg/ml	◆	1974
		Hydromorphone hydrochloride : >25 mg/ml Heparin sodium : <12,5 UI/ml	💧	66
		Hydromorphone hydrochloride : 1 mg/ml Heparin sodium : 100 UI/ml		314
		Hydromorphone hydrochloride : <12.5 mg/ml Heparin sodium	💧	66
		Hydromorphone hydrochloride : >25 mg/ml Heparin sodium : <12,5 UI/ml	▲	66
		Hydromorphone hydrochloride : <12.5 mg/ml Heparin sodium	▲	66
		Hydromorphone hydrochloride : >10 mg/ml Heparin sodium : <1 UI/ml	💧	66
		Hydromorphone hydrochloride : 0.5 mg/ml Hetastarch : 60 mg/ml	Ⓡ	1721
		Hydromorphone hydrochloride Hyaluronidase		3184
		Hydromorphone hydrochloride : 2 >> 40 mg/ml Hyaluronidase : 150 UI/ml	▲◆	9
		Hydromorphone hydrochloride : 0.5 mg/ml Hydroxyzine dihydrochloride : 4 mg/ml	◆	1974
		Hydromorphone hydrochloride : 1 mg/ml Isavuconazonium sulfate : 1.5 mg/ml	▲◆	3829
		Hydromorphone hydrochloride : 0.2 mg/ml Kanamycin sulfate : 2.5 mg/ml	◆	405
		Hydromorphone hydrochloride : 0.2 mg/ml Ketamine hydrochloride : 0.2 >> 1 mg/ml	▲	2336
		Hydromorphone hydrochloride : 1 mg/ml Ketorolac tromethamine : 30 mg/ml	∅	216
		Hydromorphone hydrochloride : 1 mg/ml Ketorolac tromethamine : 15 mg/ml	∅	216
		Hydromorphone hydrochloride : 10 mg/ml Ketorolac tromethamine : 30 mg/ml	∅	216
		Hydromorphone hydrochloride : 10 mg/ml Ketorolac tromethamine : 15 mg/ml	∅	216
		Hydromorphone hydrochloride : 0.5 mg/ml Ketorolac tromethamine : 1 mg/ml	◆	1974
		Hydromorphone hydrochloride : 1 mg/ml Labetalol hydrochloride : 2 mg/ml		314
		Hydromorphone hydrochloride : 0.5 mg/ml Lansoprazole : 0.55 mg/ml	▲	1625
		Hydromorphone hydrochloride : 2 mg/ml Levofloxacin : 5 mg/ml	∅	2335
		Hydromorphone hydrochloride : 10 mg/ml Levosimendan : 2,5 mg/ml		4389

	Hydromorphone hydrochloride : 0.5 mg/ml Linezolid : 2 mg/ml	∅	1925
	Hydromorphone hydrochloride : 0.5 mg/ml Lorazepam : 0.1 mg/ml	♦	1974
	Hydromorphone hydrochloride : 2 >> 40 mg/ml Lorazepam : 4 mg/ml	∅	1497
	Hydromorphone hydrochloride : 1 mg/ml Lorazepam : 0.5 mg/ml		314
	Hydromorphone hydrochloride : 2 mg/ml Magnesium sulfate : 16,67 >> 100 mg/ml	♦	517
	Hydromorphone hydrochloride : 0.5 mg/ml Melphalan : 0.1 mg/ml	▲	169
	Hydromorphone hydrochloride : 10 mg/ml Meropenem : 50 mg/ml	💧	4319
	Hydromorphone hydrochloride Metamizol sodium		2364
	Hydromorphone hydrochloride : 0.5 mg/ml Metoclopramide hydrochloride : 5 mg/ml	♦	1974
	Hydromorphone hydrochloride : 0.2 mg/ml Metronidazole : 5 mg/ml	♦	405
	Hydromorphone hydrochloride : 0.5 mg/ml Micafungin : 1.5 mg/ml	▲	2108
	Hydromorphone hydrochloride : 0.5 >> 45 mg/ml Midazolam hydrochloride : 0.1 >> 4.5 mg/ml	▲♦	345
	Hydromorphone hydrochloride : 0.5 mg/ml Midazolam hydrochloride : 0.2 mg/ml	♦	1974
	Hydromorphone hydrochloride : 1 mg/ml Midazolam hydrochloride : 2 mg/ml		314
	Hydromorphone hydrochloride : 1 mg/ml Milrinone lactate : 0.2 mg/ml		314
	Hydromorphone hydrochloride : 0.2 mg/ml Minocycline hydrochloride : 0.2 mg/ml	♦	405
	Hydromorphone hydrochloride : 1 mg/ml Morphine sulfate : 2 mg/ml		314
	Hydromorphone hydrochloride : 0.2 mg/ml Moxalactam : 20 mg/ml	♦	405
	Hydromorphone hydrochloride : 0.2 mg/ml Nafcillin sodium : 20 mg/ml	♦	405
	Hydromorphone hydrochloride : 10 mg/ml Naloxone hydrochloride : 0.4 mg/ml	∅	3408
	Hydromorphone hydrochloride : 1 mg/ml Nicardipine hydrochloride : 1 mg/ml		314
	Hydromorphone hydrochloride : 1 mg/ml Nitroglycerin : 0.4 mg/ml		314
	Hydromorphone hydrochloride : 1 mg/ml Norepinephrine bitartrate : 0.128 mg/ml		314
	Hydromorphone hydrochloride : 0,5 mg/ml Ondansetron hydrochloride : 0,1 & 1 mg/ml	▲	6
	Hydromorphone hydrochloride : 0.5 mg/ml Ondansetron hydrochloride : 1 mg/ml	▲	334
	Hydromorphone hydrochloride : 0.2 mg/ml Oxacillin sodium : 20 mg/ml	♦	405

		Hydromorphone hydrochloride : 0,5 mg/ml Oxaliplatin : 0,5 mg/ml		1662
		Hydromorphone hydrochloride : 0.5 mg/ml Paclitaxel : 1.2 mg/ml		248
		Hydromorphone hydrochloride : 0.5 mg/ml Palonosetron hydrochloride : 50 µg/ml		2196
		Hydromorphone hydrochloride Pantoprazole sodium		2090
		Hydromorphone hydrochloride : 2 mg/ml Paracetamol : 10 mg/ml		3571
		Hydromorphone hydrochloride : 10 mg/ml Paracetamol : 10 mg/ml		4742
		Hydromorphone hydrochloride Parecoxib sodium		3504
		Hydromorphone hydrochloride : 0.5 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Hydromorphone hydrochloride : 0.2 mg/ml Penicillin G potassium : 0.1 MUI/ml		405
		Hydromorphone hydrochloride : 0.5 mg/ml Phenobarbital sodium : 2 mg/ml		1974
		Hydromorphone hydrochloride : 2 >> 40 mg/ml Phenobarbital sodium : 120 mg/ml		226
		Hydromorphone hydrochloride : 0.5 mg/ml Phenytoin sodium : 2 mg/ml		1974
		Hydromorphone hydrochloride : 2 >> 40 mg/ml Phenytoin sodium : 50 mg/ml		226
		Hydromorphone hydrochloride : 0.2 mg/ml Piperacillin sodium : 60 mg/ml		405
		Hydromorphone hydrochloride : 0.5 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Hydromorphone hydrochloride : 1 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Hydromorphone hydrochloride Posaconazole		4380
		Hydromorphone hydrochloride : 5 >> 20 mg/ml Potassium chloride : 500 & 1000 mEq/l		66
		Hydromorphone hydrochloride : 25 mg/ml Potassium chloride : 1000 mEq/l		66
		Hydromorphone hydrochloride : 0,5 mg/ml Prochlorperazine edysilate : 1,5 mg/ml		767
		Hydromorphone hydrochloride : 2 >> 40 mg/ml Prochlorperazine edysilate : 5 mg/ml		1497
		Hydromorphone hydrochloride : 1 mg/ml Promethazine hydrochloride : 0.3 mg/ml		795
		Hydromorphone hydrochloride : 0.5 mg/ml Propofol : 10 mg/ml		300
		Hydromorphone hydrochloride : 1 mg/ml Ranitidine hydrochloride : 1 mg/ml		314
		Hydromorphone hydrochloride : 2 mg/ml Ranitidine hydrochloride : 25 mg/ml		58
		Hydromorphone hydrochloride : 1 mg/ml Remdesivir : 1 mg/ml		4768

		Hydromorphone hydrochloride : 10 mg/ml Salbutamol sulfate : 1 mg/ml	∅	3216
		Hydromorphone hydrochloride : 0.5 mg/ml Sargramostim : 10 µg/ml		335
		Hydromorphone hydrochloride : 0.5 mg/ml Scopolamine hydrobromide : 0.05 mg/ml		1974
		Hydromorphone hydrochloride : 1 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Hydromorphone hydrochloride : 0,1 & 1 mg/ml Tacrolimus : 5 & 20 µg/ml		814
		Hydromorphone hydrochloride : 1 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Hydromorphone hydrochloride : 0.5 mg/ml Teniposide : 0.1 mg/ml		905
		Hydromorphone hydrochloride : 10 mg/ml Thiopental sodium : 25 mg/ml		3767
		Hydromorphone hydrochloride : 1 mg/ml Thiopental sodium : 25 mg/ml		314
		Hydromorphone hydrochloride : 0.5 mg/ml Thiotepa : 1 mg/ml		249
		Hydromorphone hydrochloride : 0.2 mg/ml Tobramycin sulfate : 0.8 mg/ml		405
		Hydromorphone hydrochloride : 2 mg/ml Vancomycin hydrochloride : 4 mg/ml		2335
		Hydromorphone hydrochloride : 0.2 mg/ml Vancomycin hydrochloride : 5 mg/ml		405
		Hydromorphone hydrochloride : 1 mg/ml Vecuronium bromide : 1 mg/ml		314
		Hydromorphone hydrochloride : 0.016 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
		Hydromorphone hydrochloride : 0.5 mg/ml Vinorelbine tartrate : 1 mg/ml		84



Voie d'administration



Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
5	Revue	Stiles ML, Allen LV Jr, Prince SJ. Stability of deferoxamine mesylate, floxuridine, fluorouracil, hydromorphone hydrochloride, lorazepam, and midazolam hydrochloride in polypropylene infusion-pump syringes. Am J Health-Syst Pharm 1996 ; 53: 1583-1588.

6	Revue	Trissel LA, Xu QA, Martinez JF, Fox JL. Compatibility and stability of ondansetron hydrochloride with morphine sulfate and with hydromorphone hydrochloride in 0.9% sodium chloride injection at 4, 22 and 32°C. Am J Hosp Pharm 1994 ; 51: 2138-2142.
9	Revue	Walker SE, Lau DWC. Compatibility and stability of hyaluronidase and hydromorphone. Can J Hosp Pharm 1992 ; 45: 187-192.
57	Revue	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
58	Revue	Parker WA. Physical compatibility of ranitidine HCl with preoperative injectable medications. Can J Hosp Pharm 1985 ; 38: 160-161.
66	Revue	Avelar MA, Walker SE. Stability and compatibility of reconstituted hydromorphone with potassium chloride or heparin. Can J Hosp Pharm 1996 ; 49: 140-145.
73	Revue	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
91	Revue	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
93	Revue	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
120	Revue	Walker SE, Coons C, Matte D, DeAngelis C, Iazzetta J, Kolos C, Birkhans B. Hydromorphone and morphine stability in portable infusion pump cassettes and minibags. Can J Hosp Pharm 1988 ; 41: 177-182.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
215	Revue	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
216	Revue	Huang E, Anderson RP. Compatibility of hydromorphone hydrochloride with haloperidol lactate and ketorolac tromethamine. Am J Hosp Pharm 1994 ; 51: 2963.

221	Revue	Neels JT. Compatibility of bupivacaine hydrochloride with hydromorphone hydrochloride or morphine sulfate. Am J Hosp Pharm 1992 ; 49: 2149.
226	Revue	Walker SE, DeAngelis C, Iazzetta J. Stability and compatibility of combinations of hydromorphone and a second drug. Can J Hosp Pharm 1991 ; 44: 289-295.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Revue	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	Revue	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
306	Revue	Christen C, Johnson CE, Walters JR. Stability of bupivacaine hydrochloride and hydromorphone hydrochloride during simulated epidural coadministration. Am J Health-Syst Pharm 1996 ; 53: 170-173.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
314	Revue	Chiu MF, Schwartz ML. Visual compatibility of injectable drugs used in the intensive care unit. Am J Health-Syst Pharm 1997 ; 54: 64-65.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Revue	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.

345	Revue	Walker SE, Meinders A, Tailor H. Stability and compatibility of reconstituted sterile hydromorphone with midazolam. Can J Hosp Pharm 1996 ; 49: 290-298.
389	Revue	Walker SE, DeAngelis C, Iazzetta J, Eppel JG. Compatibility of dexamethasone sodium phosphate with hydromorphone hydrochloride or diphenhydramine hydrochloride. Am J Hosp Pharm 1991 ; 48: 2161-2166.
405	Revue	Nieves-Cordero AL, Luciw HM, Souney PF. Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1985 ; 42: 1108-1109.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
513	Revue	Xu QA, Trissel LA, Martinez JF. Stability and compatibility of fluorouracil with morphine sulfate and hydromorphone hydrochloride. Ann Pharmacotherapy 1996 ; 30: 756-761.
517	Revue	Letourneau M. Visual compatibility of magnesium sulfate with narcotic analgesics. Am J Hosp Pharm 1992 ; 49: 838-839.
767	Revue	Trinkle R. Compatibility of hydromorphone and prochlorperazine, and irritation due to subcutaneous prochlorperazine infusion. Ann Pharmacotherapy 1997 ; 31: 789-790.
795	Revue	Henderson F. 21-day compatibility of hydromorphone hydrochloride and promethazine hydrochloride in a cassette. Am J Health-Syst Pharm 1996 ; 53: 2338-2339.
814	Revue	Johnson CE, VandenBussche HL, Chio CC, Jacobson PA. Stability of tacrolimus with morphine sulfate, hydromorphone hydrochloride, and ceftazidime during simulated intravenous coadministration. Am J Health-Syst Pharm 1999 ; 56: 164-169.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1057	Revue	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1438	Revue	Souney PF, Solomon MA, Stancher D. Visual compatibility of cimetidine hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1984 ; 41: 1840-1841.

1496	Revue	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1497	Revue	Walker SE, Iazetta J, DeAngelis C, Lau DWC. Stability and compatibility of combinations of hydromorphone and dimenhydrinate lorazepam or prochlorperazine. Can J Hosp Pharm 1993 ; 46: 61-65.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1706	Revue	Trissel LA, Xu QA. Physical and chemical stability of hydromorphone hydrochloride 1.5 and 80 mg/ml packaged in plastic syringes. Int J Pharm Compound 2002 ; 6: 74-76.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1803	Revue	Trissel LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1867	Revue	Hildebrand KR, Elsberry DE, Anderson VC. Stability and compatibility of hydromorphone hydrochloride in an implantable infusion system. J Pain Symptom Manage 2001 ; 22, 6: 1042-1047.
1925	Revue	Trissel LA, Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1931	Revue	Donnelly RF. Physical compatibility and chemical stability of bupivacaine and hydromorphone in polypropylene syringes. Can J Hosp Pharm 2004 ; 4: 230-235.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1974	Revue	Chandler SW, Trissel LA, Weinstein SM Combined administration of opioids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility. J Pain Symptom Manage 1996 ; 12, 3: 168-171.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2087	Revue	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.

2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2108	Revue	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2166	Revue	Nassr S, Dubuc MC, Lavoie P, Brazier JL. HPLC-DAD methods for studying the stability of solutions containing hydromorphone, ketorolac, haloperidol, midazolam, famotidine, metoclopramide, dimenhydrinate and scopolamine. J Liquid Chrom Rel Technol 2003 ; 26, 17: 2909-2929.
2196	Revue	Trissel LA, Trusley C, Ben M, Kupiec TC. Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during Y-site administration. Am J Health-Syst Pharm 2007 ; 64, 11: 1209-1213.
2233	Revue	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2251	Revue	Shields D, Montenegro R, Ragusa M. Chemical stability of admixtures combining ziconotide with morphine or hydromorphone during simulated intrathecal administration. Neuromodulation 2005 ; 8, 4: 257-263.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmore T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2305	Revue	Bianchi F, Ginggen A, Tardy Y. Stability and compatibility of drug mixtures in an implantable infusion system. Anaesthesia 2008 63, 9: 972-978.
2335	Revue	Canann D, Tyler L.S, Barker B, Condie C. Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients Am J Health-Syst Pharm 2009 ; 66, 8: 727-729
2336	Revue	Ensom M.H.H, Decarie D, Leung K, Montgomery C Stability of Hydromorphone–Ketamine Solutions in Glass Bottles, Plastic Syringes, and IV Bags for Pediatric Use Can J Hosp Pharm 2009 ; 62, 2: 112-118.
2364	Poster	Müller S, Trittler R, Schubert R, Strehl E. Hydromorphone and dipyrone in PCA devices: Is still a therapy with hydromorphone? PharmSciFair 2009
2659	Revue	Khondkar D, Chopra P, McArter JP, Rosen JA, Li SK. Chemical stability of hydromorphone hydrochloride in patient-controlled analgesia injector. Int J Pharm Compound 2010 ; 14, 2: 160-164.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3131	Revue	Donnelly RF, Wong K, Spencer J. Physical compatibility of high-concentration bupivacaine with hydromorphone, morphine and fentanyl. Can J Hosp Pharm 2010 ; 63, 2: 154-155.
3184	Laboratoire	Hyaluronidase (Hyalase®) - Summary of Product characteristics.

3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3504	Laboratoire	Parecoxib (Dynastat®) - Summary of Product Characteristics Pfizer 2012
3571	Revue	Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47.
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftazolidime/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavanazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomicin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4200	Revue	Macorigh C, Guibbert V, Casanova M, Haenni C. Stability study of hydromorphone and bupivacaine mixture by HPLC-UV. EJHP 2018
4230	Poster	Perls W, Law S, Iazetta J, Walker S. Stability of 0.2 and 10 mg/mL Hydromorphone Solutions In CADD reservoirs, PVC and Ethylene/Propylene Co-Polymer (PAB) Bags at Room Temperature (23°C°). Prof Practice Conference - Canadian Society of PH 2017
4303	Revue	Anderson C, MacKay M. Stability of Fentanyl Citrate, Hydromorphone Hydrochloride, Ketamine Hydrochloride, Midazolam, Morphine Sulfate, and Pentobarbital Sodium in Polypropylene Syringes. Pharmacy 2015 3, 379-385.






4319	Revue	Lessard J-J, Caron E, Schérier H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4380	Laboratoire	Posaconazole (Noxafil®) - Summary of Product Characteristics Merck Sharp & Dohme Limited 2019
4389	Revue	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévamisendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4434	Revue	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4507	Revue	Ross E, Salinas A, Petty K, Her C, Carpenter J. Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing. Am J Health-Syst Pharm 2020 ;77,23:1980-1985
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4650	Laboratoire	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4664	Revue	Harder M, Fiegl-Lechner A, Oberacher H, Horvath U.E.I, Schlager A, Jeske M, Kerndler S, Schüllner F, Bonn G.F, Rainer M. Stability evaluation of morphine, hydromorphone, metamizole and esketamine containing analgesic mixtures applied for patient-controlled analgesia in hospice and palliative care. Biomed Chromatogr 2022 ;e5340.
4666	Revue	Lee C.H, Kim A.R, Lee M.K, Oh J.S, Lee D.K, Choi S.S. Intravenous patient-controlled analgesia: in vitro stability profiles of mixtures containing fentanyl, hydromorphone, oxycodone, nefopam, ondansetron, and ramosetron. J Anal Sci Tech 2020 ; 11: 32.
4667	Revue	Ping L, Juan H, Li R-L, Feng Z-Y, Zhou X-J, Liu M-F, Jing B, Jian L. Stability of Hydromorphone Hydrochloride and Morphine under Different Clinical Infusion Conditions. Int J Pharm Pharm Sci 2019 ;81(6):1140-114
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4746	Poster	Shead K, Derrick H, Lyons D, Law S, Ma N.H. Stability and Compatibility of Bupivacaine and Hydromorphone in PVC and non-DEHP bags for 30 days at 4°C and 25°C. 2023
4768	Revue	Kondo M, Genpei M, Watanabe K, Yoshida M, Tagui N, Fukao S, Sugaya K, Takase H. Y-site injection physical compatibility of remdesivir with select intravenous drugs used in palliative care and for treating coronavirus disease 2019. Journal of Nippon Medical school 2023

4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
------	-------	--



Dictionnaire

 Antalgique	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Verre
 Non précisé	 A l'abri de la lumière
 Jour	 Polyvinyl chlorure
 NaCl 0,9% ou glucose 5%	 Non précisée
 Chlorure de sodium 0,9%	 Polyolefine
 Seringue polypropylène	 Lumière
 Heure	 Aucun
 Non précisé	 Avec ou sans lumière
 Stabilité en mélange	 Solvant
 Molécule	 Glucose 5%
 Polyéthylène	 Elastomère en polyisoprène
 Facteur influençant la stabilité	Nutrition parentérale (mélange ternaire)
 Provoque	 Dégradation
 Compatibilités	 Compatible
 Perte de turbidité	 Incompatible
 Précipitation immédiate	 Eau pour préparation injectable
Nutrition parentérale (mélange binaire)	 NaCl 0,9% + bactériostatique
 Instabilité de l'émulsion immédiate	RL Ringer lactate
 Incompatibilité non précisée	 Précipitation en 2 heures
 Turbidité à 24 heures	 Solvant spécifique
 Instabilité chimique	 Précipitation en 1 heure
 Changement de couleur après 1 heure	 Précipitation en 4 heures
 Précipitation en 30 minutes	 Voie d'administration
 Intraveineuse	 Perfusion intraveineuse

 Intramusculaire	 Sous cutanée
 Perfusion sous-cutanée	 Bibliographie
 Dictionnaire	